The Technical Analyst
ReShape Lifesciences Inc [RSLS]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Medical Devices
ReShape Lifesciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-9.58% $2.79
America/New_York / 27 mar 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5.00 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Mar 29, 2023 |
| SharesOutstanding: | 1.794 mill |
| Avg Daily Volume: | 0.881 mill |
| RATING 2023-03-27 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE 0 | industry: PE 229.20 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$94.74 (3 301.75%) $91.95 |
| Date: 2023-03-28 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.702 - 3.87 ( +/- 38.89%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-02-28 | Stankovich Thomas | Sell | 103 | Common Stock, $0.001 par value per share |
| 2023-02-02 | Stankovich Thomas | Sell | 157 | Common Stock, $0.001 par value per share |
| 2023-01-24 | Stankovich Thomas | Sell | 110 | Common Stock, $0.001 par value per share |
| 2023-01-24 | Stankovich Thomas | Sell | 48 | Common Stock, $0.001 par value per share |
| 2022-12-01 | Stankovich Thomas | Sell | 2 213 | Common Stock, $0.001 par value per share |
| INSIDER POWER |
|---|
| 21.80 |
| Last 100 transactions |
| Buy: 7 997 510 | Sell: 3 128 727 |
Forecast:
16:00 - $2.80
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.80
Forecast 2: 16:00 - $2.80
Forecast 3: 16:00 - $2.80
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.79 (-9.58% ) |
| Volume | 0.126 mill |
| Avg. Vol. | 0.881 mill |
| % of Avg. Vol | 14.26 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For RSLS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
RSLS
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Last 10 Buy Signals
Latest Press Releases
2023-03-23 08:30:00 - Press Release
Reshape Lifesciences Announces Formation Of International Scientific Advisory Board
Top industry experts in bariatric surgery and obesity will help solidify reshape's position as the premier physician-led weight loss and metabolic health solutions company top industry experts in bariatric surgery and obesity will help solidify reshape's position as the premier physician-led weight loss and metabolic health solutions company
2023-02-08 12:07:00 - Press Release
Reshape Lifesciences Announces Closing Of Upsized $10.2 Million Underwritten Public Offering
San clemente, calif., feb. 08, 2023 (globe newswire) -- reshape lifesciences inc. (nasdaq: rsls), the premier physician-led weight loss and metabolic health solutions company, today announced the closing of its upsized underwritten public offering of 1,275,000 units, with each unit consisting of one share of its common stock, or one pre-funded warrant to purchase one share of its common stock, and one warrant to purchase one and one-half shares of its common stock. each unit was sold at a public offering price of $8.00. the warrants in the units are immediately exercisable at a price of $8.00 per share and expire five years from the date of issuance. alternatively, each warrant will become exercisable for 0...
2023-02-06 08:30:00 - Press Release
Reshape Lifesciences Announces Pricing Of Upsized $10.2 Million Underwritten Public Offering
San clemente, calif., feb. 06, 2023 (globe newswire) -- reshape lifesciences inc. (nasdaq: rsls), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its upsized underwritten public offering of 1,275,000 units, with each unit consisting of one share of its common stock, or one pre-funded warrant to purchase one share of its common stock, and one warrant to purchase one and one-half shares of its common stock. each unit is being sold at a public offering price of $8.00. the warrants in the units will be immediately exercisable at a price of $8.00 per share and will expire five years from the date of issuance. alternatively, each warrant will become exercisable for 0...
2022-12-22 08:30:00 - Press Release
Reshape Lifesciences Announces 1-for-50 Reverse Stock Split effective As Of Commencement Of Trading On December 23, 2022
San clemente, calif., dec. 22, 2022 (globe newswire) -- reshape lifesciences inc. (nasdaq: rsls), the premier physician-led weight loss and metabolic health solutions company, today announced that its board of directors has declared a 1-for-50 reverse stock split of the company's common stock, which will be effective for trading purposes upon the commencement of trading on december 23, 2022. at that time, each 50 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. as a result of the reverse stock split, proportional adjustments will be made to the number of shares of common stock issuable upon exercise or conversion, and the per share exercise or conversion price of the company's outstanding warrants, stock options and convertible preferred stock, in each case in accordance with their terms...
2022-11-14 07:30:00 - Press Release
Reshape Lifesciences™ Reports Third Quarter 2022 Financial Results And Provides Corporate Update
Conference call to be held at 8:00 am et today conference call to be held at 8:00 am et today
Latest News
2023-03-22 08:30:00 - GlobeNewsWire
ReShape Lifesciences® to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
Conference Call to be Held at 8:00 am ET on Wednesday, March 29, 2023 Conference Call to be Held at 8:00 am ET on Wednesday, March 29, 2023
2023-03-15 08:30:00 - GlobeNewsWire
ReShape Lifesciences® to Present at the Q2 Virtual Investor Summit
SAN CLEMENTE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present a company overview at the Q2 Virtual Investor Summit on Wednesday, March 29 at 1:00 pm ET. During the virtual presentation, management will highlight the Company's three pillars for growth and its portfolio of products that address the entire weight loss continuum including the anatomy-sparing Lap-Band®.
2023-02-24 06:30:58 - InvestorPlace
7 Stocks That Just Have No Hope Left
Let's face it – there are some stocks to sell that just have no hope left. Hope is a great thing.
2023-02-06 09:23:56 - InvestorPlace
Why Is ReShape Lifesciences (RSLS) Stock Down 63% Today?
ReShape Lifesciences (NASDAQ: RSLS ) stock is falling hard on Monday as the company's shares pull back from a rally on Friday. RSLS stock saw a massive gain on Friday that had it finishing out normal trading hours more than 170% higher.
2023-02-03 13:52:10 - InvestorPlace
5 Investors Betting Big on Reshape Lifesciences (RSLS) Stock
One of the biggest movers in today's session, Reshape Lifesciences (NASDAQ: RSLS ) is absolutely skyrocketing. At the time of writing, RSLS stock has surged an impressive 150% in today's session alone.
2023-02-03 07:58:02 - InvestorPlace
Why Is Reshape Lifesciences (RSLS) Stock Up 136% Today?
Reshape Lifesciences (NASDAQ: RSLS ) stock is rocketing higher on Friday as a filing mixup shines a light on the company's shares. According to a filing with the U.S. Securities and Exchange Commission (SEC), Reshape Lifesciences is seeking the withdrawal of two filings made with the agency on Thursday.
2022-11-14 12:52:03 - Seeking Alpha
ReShape Lifesciences Inc. (RSLS) Q3 2022 Earnings Call Transcript
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Paula Schwartz - Managing Director-Rx Communications Group Paul Hickey - President & Chief Executive Officer Thomas Stankovich - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Ben Haynor - AGP Operator Good morning and thank you for joining the ReShape Lifesciences Third Quarter 2022 Conference Call. I would now like to turn the call over to Paula Schwartz from Rx Communications.
2022-11-07 13:22:00 - GlobeNewsWire
ReShape Lifesciences™ to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
Conference Call to be Held at 8:00 am ET on Monday, November 14, 2022 Conference Call to be Held at 8:00 am ET on Monday, November 14, 2022
2022-11-02 09:11:00 - GlobeNewsWire
ReShape Lifesciences to Present at the Q4 Investor Summit
SAN CLEMENTE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present a company overview at the Q4 Investor Summit on Monday, November 14 at 1:30 p.m. ET. During the presentation, management will highlight its next-generation, anatomy-sparing, Lap-Band® program and the nationwide, reshapecare™ virtual health coaching program.
2022-08-15 20:17:07 - Seeking Alpha
ReShape Lifesciences Inc. (RSLS) CEO Paul Hickey on Q2 2022 Results - Earnings Call Transcript
ReShape Lifesciences Inc. (NASDAQ:RSLS ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Michael Miller - Rx Communications, Investor Relations Paul Hickey - President and Chief Executive Officer Tom Stankovich - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Good afternoon. Thank you for joining the ReShape Lifesciences Second Quarter 2022 Conference Call.